Overall survival (OS) among Medicare beneficiaries receiving sipuleucel-T (sip-T) versus oral treatment for metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract

sustainable development goals

publication date

  • February 20, 2020

webpage

published in

volume

  • 38

issue

  • 6